201 related articles for article (PubMed ID: 17162625)
21. Body dysmorphic disorder and depression: theoretical considerations and treatment strategies.
Phillips KA
Psychiatr Q; 1999; 70(4):313-31. PubMed ID: 10587987
[TBL] [Abstract][Full Text] [Related]
22. Clinical predictors of drug nonresponse in obsessive-compulsive disorder.
Shetti CN; Reddy YC; Kandavel T; Kashyap K; Singisetti S; Hiremath AS; Siddequehusen MU; Raghunandanan S
J Clin Psychiatry; 2005 Dec; 66(12):1517-23. PubMed ID: 16401151
[TBL] [Abstract][Full Text] [Related]
23. Body dysmorphic disorder: an obsessive-compulsive spectrum disorder, a form of affective spectrum disorder, or both?
Phillips KA; McElroy SL; Hudson JI; Pope HG
J Clin Psychiatry; 1995; 56 Suppl 4():41-51; discussion 52. PubMed ID: 7713865
[TBL] [Abstract][Full Text] [Related]
24. An open-label study of escitalopram in body dysmorphic disorder.
Phillips KA
Int Clin Psychopharmacol; 2006 May; 21(3):177-9. PubMed ID: 16528140
[TBL] [Abstract][Full Text] [Related]
25. [Treatment-resistant anxiety disorders: A literature review of drug therapy strategies].
Ammar G; Naja WJ; Pelissolo A
Encephale; 2015 Jun; 41(3):260-5. PubMed ID: 25439852
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and correlates of major depressive disorder in individuals with body dysmorphic disorder.
Phillips KA; Didie ER; Menard W
J Affect Disord; 2007 Jan; 97(1-3):129-35. PubMed ID: 16893571
[TBL] [Abstract][Full Text] [Related]
27. Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.
Landeros-Weisenberger A; Bloch MH; Kelmendi B; Wegner R; Nudel J; Dombrowski P; Pittenger C; Krystal JH; Goodman WK; Leckman JF; Coric V
J Affect Disord; 2010 Feb; 121(1-2):175-9. PubMed ID: 19577308
[TBL] [Abstract][Full Text] [Related]
28. Issues in the pharmacological treatment of obsessive-compulsive disorder.
Math SB; Janardhan Reddy YC
Int J Clin Pract; 2007 Jul; 61(7):1188-97. PubMed ID: 17511795
[TBL] [Abstract][Full Text] [Related]
29. An open-label study of citalopram in body dysmorphic disorder.
Phillips KA; Najjar F
J Clin Psychiatry; 2003 Jun; 64(6):715-20. PubMed ID: 12823088
[TBL] [Abstract][Full Text] [Related]
30. Severe obsessive-compulsive disorder with and without body dysmorphic disorder: clinical correlates and implications.
Stewart SE; Stack DE; Wilhelm S
Ann Clin Psychiatry; 2008; 20(1):33-8. PubMed ID: 18297584
[TBL] [Abstract][Full Text] [Related]
31. Prevalence, demographic and clinical characteristics of body dysmorphic disorder among psychiatric outpatients with mood, anxiety or somatoform disorders.
van der Meer J; van Rood YR; van der Wee NJ; den Hollander-Gijsman M; van Noorden MS; Giltay EJ; Zitman FG
Nord J Psychiatry; 2012 Sep; 66(4):232-8. PubMed ID: 22029732
[TBL] [Abstract][Full Text] [Related]
32. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
Bloch MH; Landeros-Weisenberger A; Kelmendi B; Coric V; Bracken MB; Leckman JF
Mol Psychiatry; 2006 Jul; 11(7):622-32. PubMed ID: 16585942
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcome in adults with obsessive-compulsive disorder.
Bloch MH; Green C; Kichuk SA; Dombrowski PA; Wasylink S; Billingslea E; Landeros-Weisenberger A; Kelmendi B; Goodman WK; Leckman JF; Coric V; Pittenger C
Depress Anxiety; 2013 Aug; 30(8):716-22. PubMed ID: 23532944
[TBL] [Abstract][Full Text] [Related]
34. The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder.
Diniz JB; Costa DL; Cassab RC; Pereira CA; Miguel EC; Shavitt RG
J Psychopharmacol; 2014 Jun; 28(6):603-11. PubMed ID: 24288238
[TBL] [Abstract][Full Text] [Related]
35. Neuropsychological performance in medicated vs. unmedicated patients with obsessive-compulsive disorder.
Mataix-Cols D; Alonso P; Pifarré J; Menchón JM; Vallejo J
Psychiatry Res; 2002 Apr; 109(3):255-64. PubMed ID: 11959362
[TBL] [Abstract][Full Text] [Related]
36. Suicidal ideation and suicide attempts in body dysmorphic disorder.
Phillips KA; Coles ME; Menard W; Yen S; Fay C; Weisberg RB
J Clin Psychiatry; 2005 Jun; 66(6):717-25. PubMed ID: 15960564
[TBL] [Abstract][Full Text] [Related]
37. Pharmacologic treatment of body dysmorphic disorder.
Phillips KA
Psychopharmacol Bull; 1996; 32(4):597-605. PubMed ID: 8993080
[TBL] [Abstract][Full Text] [Related]
38. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders.
Hoehn-Saric R; Ninan P; Black DW; Stahl S; Greist JH; Lydiard B; McElroy S; Zajecka J; Chapman D; Clary C; Harrison W
Arch Gen Psychiatry; 2000 Jan; 57(1):76-82. PubMed ID: 10632236
[TBL] [Abstract][Full Text] [Related]
39. Body dysmorphic disorder: does it have a psychotic subtype?
McElroy SL; Phillips KA; Keck PE; Hudson JI; Pope HG
J Clin Psychiatry; 1993 Oct; 54(10):389-95. PubMed ID: 8262881
[TBL] [Abstract][Full Text] [Related]
40. Treatment of obsessive-compulsive disorder in patients who have comorbid major depression.
Abramowitz JS
J Clin Psychol; 2004 Nov; 60(11):1133-41. PubMed ID: 15389622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
